Sign in
CompletedPhase 3

Treating Brain Swelling in Pediatric Cerebral Malaria

Key facts

Who runs it
Michigan State University
Where
Malawi1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
57 people enrolled
Started
8 Jan 2018
Ended
31 Dec 2023
Type of study
Interventional, 3 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Mechanical ventilation
  • Hypertonic saline
Record updated
17 March 2025

Who can take part

Age
6 months to 12 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Peripheral P. falciparum parasitemia of any density
  • Blantyre Coma Score ≤2
  • No evidence of meningitis on lumbar puncture
  • Consciousness not regained after correction of hypoglycemia (if hypoglycemia is present)
  • Male or female whose age on the day of screening is between 6 months and 12 years old
  • Severely increased brain volume on magnetic resonance imaging
  • Provision of consent by guardian
  • Willingness to return for 1, 6, and 12 month post-randomization follow-up visits

Who cannot take part

  • Advanced Human Immunodeficiency Virus (HIV) disease - defined as known HIV positive status and evidence of severe wasting
  • Gross malnutrition as evidenced by peripheral edema, hair color changes, or severe wasting
  • Evidence of recent head trauma by history or physical examination
  • Pneumonia as evidenced by oxygen saturation on room air of <85%
  • Gastroenteritis and shock as evidenced by capillary refill >3 seconds or skin tenting

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study evaluates the effectiveness of two interventions in Malawian children with cerebral malaria at high risk of death. One-third of the participants will receive treatment as usual, one-third will receive treatment as usual and be placed on a mechanical ventilator, and one-third will receive treatment as usual plus intravenous hypertonic saline.

The 3 groups in the trial

  • Usual careNo study treatment, for comparison

    Hospitalization in a high dependency pediatric unit with skilled nursing, intravenous artesunate followed by oral artemisinin combination therapy, intravenous fluids, nasogastric feeding, elevation of the head of the bed by 30 degrees

  • Mechanical ventilationTreatment being tested

    Hospitalization in a high dependency pediatric unit with skilled nursing, intravenous artesunate followed by oral artemisinin combination therapy, intravenous fluids, nasogastric feeding, elevation of the head of the bed by 30 degrees, along with intubation and mechanical ventilation for a maximum of 7 days

  • Hypertonic salineTreatment being tested

    Hospitalization in a high dependency pediatric unit with skilled nursing, intravenous artesunate followed by oral artemisinin combination therapy, intravenous fluids, nasogastric feeding, elevation of the head of the bed by 30 degrees, along with intravenous 3% hypertonic saline for a maximum of 7 days

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
17 March 2025